About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 392 record(s)
Req # A-2021-001719
Adverse Drug Reaction (ADR) for INSULIN GLULISINE. Report number: 961939.Organization: Health Canada
December 2022
Req # A-2021-002107
Adverse Drug Reactions (ADRs) for ABILIFY MAINTENA. Report numbers: E2B_04692692, E2B_04684256, E2B_04773776, E2B_04802064, 00970796, E2B_04766251. ADRs for SUCROFERRIC OXYHYDROXIDE. Report numbers: E2B_04691071, E2B_04777356, E2B_04817707. ADRs for PATIROMER. Report numbers: E2B_04694533, E2B_04795568, E2B_04831414. ADR for JINARC. Report number: E2B_04794185.Organization: Health Canada
December 2022
Req # A-2022-000047
Adverse Drug Reaction (ADR) for GLYCERYL TRINITRATE. Report number: E2B_05006504. ADRs for CLOPIDOGREL BISULFATE. Report numbers: E2B_04798666, E2B_04188590.Organization: Health Canada
December 2022
Req # A-2022-000177
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-102130-986.Organization: Health Canada
December 2022
Req # A-2022-000221
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-115561-42.Organization: Health Canada
December 2022
Req # A-2022-000548
Adverse Drug Reactions (ADRs) for MESALAZINE. Report numbers: 000990672, E2B_05361971, E2B_05323624, E2B_05368162, 000992474. ADRs for VYVANSE. Report numbers: E2B_05347288, 000992979. ADRs for C1 ESTERASE INHIBITOR (HUMAN). Report numbers: E2B_05309974, E2B_05344993, E2B_05349867.Organization: Health Canada
December 2022
Req # A-2022-000564
Adverse Drug Reactions (ADRs). Report numbers: E2B_03869816, E2B_05154894, 000975026, E2B_03352321, E2B_04836615, E2B_04910255, E2B_04938543, 000975659, E2B_04921222, E2B_04926643.Organization: Health Canada
December 2022
Req # A-2022-000683
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-105570-697.Organization: Health Canada
December 2022
Req # A-2022-000698
Adverse Drug Reactions (ADRs). Report numbers: E2B_04321809, E2B_02770462, E2B_05372962, E2B_05415740, E2B_05400872, E2B_05104991, E2B_05332603, E2B_05363858, E2B_05414160, E2B_05415560.Organization: Health Canada
December 2022
Req # A-2022-000719
Adverse Drug Reactions (ADRs) for OLMETEC. Report numbers: E2B_01486139, E2B_01422947, 000705509. ADR for PRINIVIL. Report number: E2B_01399419. ADRs for PROMETRIUM. Report numbers: E2B_00758389, E2B_01735915, E2B_01740582, E2B_00451784, E2B_00758389. ADR for PROPECIA. Report number: 000700926.Organization: Health Canada
December 2022